LMORX Performance — Patient Opportunity Trust, Class R
Data updated: 2026-08-31
LMORX returned +9.92% year to date and +33.63% over one year to Jun 2026. Over one year the fund beat its US Multi-Cap Blend category average: $100 grew to $134, against $116 for the category. Volatility over the past 12 months was 16.34% a year. In the 12 months to Jun 2026 the fund lost a net $101.0M, and assets reached $2.01B.
LMORX Growth of $100
What $100 invested in Patient Opportunity Trust grew to, compounded from monthly returns reported on SEC Form N-PORT, against the US Multi-Cap Blend category average over the same months.
| Period | LMORX | Category average |
|---|---|---|
| 1 year (Jul 2025 – Jun 2026) | $134 | $116 |
| Since data start (Jan 2024 – Jun 2026) | $176 | $135 |
LMORX Trailing Returns
Total returns to Jun 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +9.92% |
| 1 year | +33.63% |
| 3 years (annualised) | +25.37% |
LMORX Annual Returns
Calendar-year total returns of Patient Opportunity Trust, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jun) | +9.92% |
| 2025 | +27.07% |
| 2024 | +26.01% |
LMORX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +2.5% | −2.9% | −5.5% | +12.9% | +2.6% | +1.1% | — | — | — | — | — | — |
| 2025 | +4.8% | −4.0% | −10.0% | −4.9% | +9.4% | +10.9% | +5.5% | +7.5% | +0.9% | +2.8% | +0.5% | +2.8% |
| 2024 | −1.1% | +6.5% | +6.3% | −5.3% | +3.6% | +0.1% | +2.9% | −0.4% | +3.1% | +3.2% | +9.6% | −4.2% |
LMORX Risk
Risk measures from monthly returns over Jul 2025 – Jun 2026.
- 1-year volatility (annualised): 16.34%
- Best month: +12.87% (Apr 2026)
- Worst month: −5.55% (Mar 2026)
LMORX Fund Flows
Monthly money in and out of Patient Opportunity Trust, from SEC Form N-PORT.
- 12-month net flow: −$101.0M
- 12-month gross sales (incl. reinvestments): $180.4M
- Sales ÷ redemptions: 0.64×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jun 2026 | $8.2M | $18.0M | −$9.8M |
| May 2026 | $7.4M | $14.2M | −$6.8M |
| Apr 2026 | $70.6M | $77.4M | −$6.8M |
| Mar 2026 | $14.0M | $20.7M | −$6.7M |
| Feb 2026 | $9.4M | $16.8M | −$7.4M |
| Jan 2026 | $14.8M | $18.8M | −$4.1M |
| Dec 2025 | $7.5M | $19.2M | −$11.7M |
| Nov 2025 | $6.8M | $16.3M | −$9.5M |
| Oct 2025 | $10.7M | $27.5M | −$16.9M |
| Sep 2025 | $15.9M | $17.4M | −$1.5M |
| Aug 2025 | $6.6M | $17.8M | −$11.2M |
| Jul 2025 | $8.6M | $17.1M | −$8.6M |
LMORX Assets Under Management
Net assets of Patient Opportunity Trust by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-06-30 | $2.01B |
| 2026-03-31 | $1.74B |
| 2025-12-31 | $1.86B |
| 2025-09-30 | $1.79B |
| 2025-06-30 | $1.58B |
| 2025-03-31 | $1.40B |
| 2024-12-31 | $1.58B |
| 2024-09-30 | $1.49B |
| 2024-06-30 | $1.44B |
| 2024-03-31 | $1.50B |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.